SAMSUNG PHARM. Co., LTD. (001360.KS)
KRW 1603.0
(0.25%)
KRW 1603.0
(0.25%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -21.68 Billion KRW | -59.47% |
| 2022 | -21.97 Billion KRW | 31.06% |
| 2021 | -36.45 Billion KRW | -24.43% |
| 2020 | -25.32 Billion KRW | -580.14% |
| 2019 | 12.42 Billion KRW | -447.66% |
| 2018 | 3.1 Billion KRW | 112.29% |
| 2017 | -4.46 Billion KRW | 59.09% |
| 2016 | -11.57 Billion KRW | -430.02% |
| 2015 | 3 Billion KRW | 115.19% |
| 2014 | -20.78 Billion KRW | -37.43% |
| 2013 | -14.41 Billion KRW | -1204.69% |
| 2012 | 1.2 Billion KRW | -11.25% |
| 2011 | 1.46 Billion KRW | -24.63% |
| 2010 | 1.95 Billion KRW | -51.29% |
| 2009 | 4 Billion KRW | 20.97% |
| 2008 | 3.3 Billion KRW | 1312.34% |
| 2007 | 291 Million KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.7 Billion KRW | 58.92% |
| 2024 Q2 | -5.72 Billion KRW | -126.15% |
| 2023 Q3 | 5.64 Billion KRW | -29.95% |
| 2023 Q4 | -4.69 Billion KRW | -183.13% |
| 2023 Q1 | -4.75 Billion KRW | -19.61% |
| 2023 FY | - KRW | -59.47% |
| 2023 Q2 | 8.06 Billion KRW | 269.64% |
| 2022 FY | - KRW | 31.06% |
| 2022 Q1 | 469.16 Million KRW | 107.37% |
| 2022 Q2 | -5.25 Billion KRW | -1219.67% |
| 2022 Q3 | -1.7 Billion KRW | 67.61% |
| 2022 Q4 | -3.97 Billion KRW | -133.55% |
| 2021 Q3 | -4.65 Billion KRW | -117.07% |
| 2021 Q1 | -1.17 Billion KRW | 81.83% |
| 2021 FY | - KRW | -24.43% |
| 2021 Q2 | -2.14 Billion KRW | -81.77% |
| 2021 Q4 | -6.36 Billion KRW | -36.88% |
| 2020 Q2 | -3.4 Billion KRW | -40.39% |
| 2020 Q4 | -6.48 Billion KRW | -506.83% |
| 2020 FY | - KRW | -580.14% |
| 2020 Q1 | -2.42 Billion KRW | 0.0% |
| 2020 Q3 | -1.06 Billion KRW | 68.6% |
| 2019 Q2 | -512.53 Million KRW | -248.71% |
| 2019 Q1 | 344.64 Million KRW | 114.14% |
| 2019 FY | - KRW | -447.66% |
| 2019 Q3 | -2.28 Billion KRW | -346.47% |
| 2018 Q4 | -2.43 Billion KRW | -137.16% |
| 2018 Q2 | 1 Billion KRW | -25.72% |
| 2018 FY | - KRW | 112.29% |
| 2018 Q1 | 1.35 Billion KRW | 150.37% |
| 2018 Q3 | -1.02 Billion KRW | -202.44% |
| 2017 Q3 | 44.45 Million KRW | 124.31% |
| 2017 Q2 | -182.84 Million KRW | -3420.95% |
| 2017 Q1 | -5.19 Million KRW | 99.89% |
| 2017 FY | - KRW | 59.09% |
| 2017 Q4 | -2.68 Billion KRW | -6130.77% |
| 2016 Q4 | -4.9 Billion KRW | -74.11% |
| 2016 FY | - KRW | -430.02% |
| 2016 Q3 | -2.81 Billion KRW | -148.23% |
| 2016 Q2 | -1.13 Billion KRW | -5.95% |
| 2016 Q1 | -1.07 Billion KRW | 46.69% |
| 2015 Q1 | 1.01 Billion KRW | 105.32% |
| 2015 Q2 | 35.56 Million KRW | -96.48% |
| 2015 Q3 | -1.44 Billion KRW | -4155.99% |
| 2015 Q4 | -2 Billion KRW | -39.17% |
| 2015 FY | - KRW | 115.19% |
| 2014 Q4 | -18.99 Billion KRW | -3460.22% |
| 2014 Q3 | -533.64 Million KRW | -416.93% |
| 2014 Q2 | 168.37 Million KRW | 453.69% |
| 2014 Q1 | 30.41 Million KRW | 100.18% |
| 2014 FY | - KRW | -37.43% |
| 2013 Q2 | 1.38 Billion KRW | -8.66% |
| 2013 Q3 | -152.01 Million KRW | -111.01% |
| 2013 Q4 | -17.13 Billion KRW | -11174.65% |
| 2013 Q1 | 1.51 Billion KRW | 194.76% |
| 2013 FY | - KRW | -1204.69% |
| 2012 Q2 | 1.17 Billion KRW | 21.02% |
| 2012 Q1 | 974 Million KRW | 706.73% |
| 2012 Q3 | 745.62 Million KRW | -36.75% |
| 2012 Q4 | -1.59 Billion KRW | -313.9% |
| 2012 FY | - KRW | -11.25% |
| 2011 FY | - KRW | -24.63% |
| 2011 Q3 | -769.75 Million KRW | -176.77% |
| 2011 Q4 | 120.73 Million KRW | 115.68% |
| 2011 Q1 | 1.12 Billion KRW | 219.82% |
| 2011 Q2 | 1 Billion KRW | -10.78% |
| 2010 Q3 | 958.3 Million KRW | 44.32% |
| 2010 FY | - KRW | -51.29% |
| 2010 Q2 | 664.01 Million KRW | -47.49% |
| 2010 Q1 | 1.26 Billion KRW | -10.94% |
| 2010 Q4 | -937.98 Million KRW | -197.88% |
| 2009 Q2 | 351.89 Million KRW | -64.64% |
| 2009 Q3 | 1.23 Billion KRW | 250.6% |
| 2009 Q1 | 995.07 Million KRW | 10.94% |
| 2009 FY | - KRW | 20.97% |
| 2009 Q4 | 1.41 Billion KRW | 15.09% |
| 2008 Q1 | 855.48 Million KRW | 1228.54% |
| 2008 Q2 | 829.67 Million KRW | -3.02% |
| 2008 FY | - KRW | 1312.34% |
| 2008 Q3 | 725 Million KRW | -12.62% |
| 2008 Q4 | 896.96 Million KRW | 23.72% |
| 2007 Q3 | -1.44 Billion KRW | -239.64% |
| 2007 Q2 | 1.03 Billion KRW | 43.51% |
| 2007 Q4 | -75.8 Million KRW | 94.74% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q1 | 718.97 Million KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 546.399% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 115.342% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 66.132% |
| HANDOK Inc. | 35.06 Billion KRW | 161.847% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | -1992.232% |
| Yuhan Corporation | 127.43 Billion KRW | 117.019% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 157.801% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 106.707% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | 534.592% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 243.453% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | 733.958% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | 579.135% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 161.115% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 546.399% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | -17.409% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | 430.857% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 56.002% |
| JW Holdings Corporation | 187.88 Billion KRW | 111.543% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 57.665% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 107.647% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 124.308% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 41.491% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | 264.18% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | 283.36% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | 216.257% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 546.399% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 139.451% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 113.151% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 124.308% |
| Yuhan Corporation | 127.43 Billion KRW | 117.019% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 164.786% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | 383.504% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 128.155% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 124.308% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 159.2% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 130.641% |
| CKD Bio Corp. | -1.63 Billion KRW | -1230.163% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 143.555% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 166.605% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 158.917% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 41.491% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 134.82% |
| Boryung Corporation | 114.28 Billion KRW | 118.976% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 29.052% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 243.453% |
| JW Lifescience Corporation | 50.82 Billion KRW | 142.668% |